Thema Aeterna Zentaris
Seite 18 von 148 Neuester Beitrag: 25.04.21 00:50 | ||||
Eröffnet am: | 14.11.15 15:59 | von: AnonymusNo. | Anzahl Beiträge: | 4.689 |
Neuester Beitrag: | 25.04.21 00:50 | von: Jenniferptay. | Leser gesamt: | 401.603 |
Forum: | Hot-Stocks | Leser heute: | 33 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 15 | 16 | 17 | | 19 | 20 | 21 | ... 148 > |
Oder sehe ich das falsch ?
Oder kommt das Doddsche Modell ?
Leckaaa!!!! nicht zu verwechseln mit "leck A..."
Outstanding Share Data
As at March 29, 2016, we had 9,928,697 common shares issued and outstanding, as well as 275,041 stock options outstanding. Warrants outstanding as at March 29, 2016 represented a total of 2,842,309 equivalent common shares (excluding any exercises of Series B Warrants under the alternate cashless exercise feature of such warrants).
http://www.sec.gov/Archives/edgar/data/1113423/...t992mda-q4x2015.htm
Tja, oder sollte man den Satz in den Klammern keinen "Wert" schenken !
Also keine Panik, das weitereAktien- Ausgaben erfolgen ist doch klar....
2.Commenting on the Company’s product-development progress, Mr. Dodd stated, “During the fourth quarter, we received very encouraging news regarding Zoptrex™ when, following a comprehensive review of the final interim efficacy and safety data, the DSMB recommended that we continue the ZoptEC Phase 3 clinical study to its conclusion. We expect to complete the ZoptEC trial in Q3 of 2016 and, if the results of the trial warrant doing so, to file the NDA for Zoptrex™ in the first half of 2017. More recently, we reported on the successful progress of the Zoptrex™ development program in China. We also initiated patient enrollment in our confirmatory Phase 3 clinical study of Macrilen™, which we expect to be the first FDA-approved test for the evaluation of adult growth hormone deficiency. We expect the confirmatory Phase 3 clinical study of Macrilen™ to be concluded in Q3 of 2016, which would permit us to submit a NDA by mid-year 2017. If the study is successful in meeting its primary endpoint, we anticipate FDA approval of Macrilen™ by as early as year-end 2017.”
Irgendwie scheint sich Dodd seiner Sache sehr sicher zu sein.
Er hegt keinen Zweifel an einer Zulassung !
Sind die Studienergebnisse so gut ?